The genetic and epigenetic differences between grade III and IV HGG such as O-6-methylguanine-DNA methyltransferase (MGMT) methylation status for GBM patients have a significant impact on treatment response and prognosis. The gene discussed is MGMT; the disease is glioblastoma.